Analgesic medication use and risk of epithelial ovarian cancer in African American women

British Journal of Cancer

Volumn 114, Issue 7, 2016, Pages 819-825

  Peres, Lauren C ^a   Camacho, Fabian ^a   Abbott, Sarah E ^a   Alberg, Anthony J ^b   Bandera, Elisa V ^c   Barnholtz Sloan, Jill ^d   Bondy, Melissa ^e   Cote, Michele L ^f   Crankshaw, Sydnee ^g   Funkhouser, Ellen ^h   Moorman, Patricia G ^g   Peters, Edward S ⁱ   Schwartz, Ann G ^f   Terry, Paul ^j   Wang, Frances ^g   Schildkraut, Joellen M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h University of Alabama at Birmingham   (United States)

ⁱ LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^j UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

more..

Author keywords

acetaminophen; African American; analgesics; aspirin; non steroidal anti inflammatory drugs; ovarian cancer

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; PROTECTIVE AGENT;

ADULT; AFRICAN AMERICAN; AGED; ARTHRITIS; ARTICLE; BREAST CANCER; CANCER RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG INDICATION; DRUG USE; EDUCATIONAL STATUS; ENDOMETRIOSIS; FAMILY HISTORY; FEMALE; FIRST DEGREE RELATIVE; HEART DISEASE; HEART INFARCTION PREVENTION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY CANCER; OVARY CARCINOMA; PELVIC INFLAMMATORY DISEASE; PHYSICAL ACTIVITY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; SMOKING; UTERINE TUBE LIGATION; ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; CASE CONTROL STUDY; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FOLLOW UP; OVARIAN NEOPLASMS; PROGNOSIS; RISK FACTOR; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; AFRICAN AMERICANS; AGED; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; PROTECTIVE AGENTS; RISK FACTORS; UNITED STATES;

EID: 84959122218     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.39     Document Type: Article

References (29)

1. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE (2001) Aspirin and epithelial ovarian cancer. Prev Med 33: 682-687.
2. Albert MA, Glynn RJ, Buring J, Ridker PM (2004) C-Reactive protein levels among women of various ethnic groups living in the United States (from the Women?s Health Study) Am J Cardiol 93: 1238-1242.
3. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C (2012) Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 23: 1403-1415.
4. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER (1998) Over-The-counter analgesics and risk of ovarian cancer. Lancet 351: 104-107.
5. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE (1998) Cyclooxygenase in biology and disease. FASEB J 12: 1063-1073.
6. Fairfield KM, Hunter DJ, Fuchs CS, Colditz GA, Hankinson SE (2002) Aspirin, other NSAIDs, and ovarian cancer risk (United States) Cancer Causes Control 13: 535-542.
7. García-Rodríguez LA, Huerta-Alvarez C (2001) Reduced risk of colorectal cancer among long-Term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 12: 88-93.
8. Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN (2007) Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol 166: 1150-1158.
9. Hannibal CG, Rossing MA, Wicklund KG, Cushing-Haugen KL (2008) Analgesic drug use and risk of epithelial ovarian cancer. Am J Epidemiol 167: 1430-1437.
10. Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, Wians FH, Grundy SM, De Lemos JA (2005) Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 46: 464-469.
11. Lacey Jr JV, Sherman ME, Hartge P, Schatzkin A, Schairer C (2004) Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer 108: 281-286.
12. Merritt MA, Green AC, Nagle CM, Webb PM, Bowtell D, Chenevix-Trench G, Green A, Webb P, DeFazio A, Gertig D, Traficante N, Moore S, Hung J, Fereday S, Harrap K, Sadkowsky T, Mellon A, Robertson R, Vanden Bergh T, Maidens J, Nattress K, Chiew YE, Stenlake A, Sullivan H, Alexander B, Ashover P, Brown S, Corrish T, Green L, Jackman L, Martin K, Ranieri B, White J, Jayde V, Bowes L, Mamers P, Schmidt T, Shirley H, Viduka S, Tran H, Bilic S, Glavinas L, Proietto A, Braye S, Otton G, Bonaventura T, Stewart J, Friedlander M, Bell D, Baron-Hay S, Ferrier A, Gard G, Nevell D, Young B, Camaris C, Crouch R, Edwards L, Hacker N, Marsden D, Robertson G, Beale P, Beith J, Carter J, Dalrymple C, Hamilton A, Houghton R, Russell P, Brand A, Jaworski R, Harnett P, Wain G, Crandon A, Cummings M, Horwood K, Obermair A, Wyld D, Nicklin J, Perrin L, Ward B, Davy M, Hall C, Dodd T, Healy T, Pittman K, Henderson D, Hyde S, Miller J, Pierdes J, Blomfield P, Challis D, McIntosh R, Parker A, Brown B, Rome R, Allen D, Grant P, Hyde S, Laurie R, Robbie M, Healy D, Jobling T, Maniolitas T, McNealage J, Rogers P, Susil B, Veitch A, Constable J, Ping Tong S, Robinson I, Simpson I, Phillips K, Rischin D, Waring P, Loughrey M, O?Callaghan N, Murray B, Billson V, Galloway S, Pyman J, Quinn M, Hammond I, McCartney A, Leung Y, Haviv I, Zeps N, Green AC, Parsons PG, Hayward N, Webb P, Purdie D, Whiteman D (2008) Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122: 170-176.
13. Moysich KB, Mettlin C, Piver MS, Natarajan N, Menezes RJ, Swede H (2001) Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 10: 903-906.
14. Murphy MA, Trabert B, Yang HP, Park Y, Brinton LA, Hartge P, Sherman ME, Hollenbeck A, Wentzensen N (2012) Non-steroidal antiinflammatory drug use and ovarian cancer risk: findings from the NIHAARP Diet and Health Study and systematic review. Cancer Causes Control 23: 1839-1852.
15. Neill AS, Nagle CM, Protani MM, Obermair A, Spurdle AB, Webb PM (2013) Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and metaanalysis. Int J Cancer 132: 1146-1155.
16. Ness RB, Cottreau C (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91: 1459-1467.
17. Ni X, Ma J, Zhao Y, Wang Y, Wang S (2013) Meta-Analysis on the association between non-steroidal anti-inflammatory drug use and ovarian cancer. Br J Clin Pharmacol 75: 26-35.
18. Paalani M, Lee JW, Haddad E, Tonstad S (2011) Determinants of inflammatory markers in bi-ethnic population. Ethn Dis 21: 142-149.
19. Pinheiro SP, Tworoger SS, Cramer DW, Rosner BA, Hankinson SE (2009) Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. Am J Epidemiol 169: 1378-1387.
20. Rosenberg L, Palmer JR, Rao RS, Coogan PF, Strom BL, Zauber AG, Stolley PD, Shapiro S (2000) A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev 9: 933-937.
21. Rothwell PM, Price JF, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JFF, Wilson M, Mehta Z, Meade TW (2012) Short-Term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379: 1602-1612.
22. Schildkraut JM, Alberg AJ, Bandera EV, Barnholtz-sloan J, Bondy M, Cote ML, Funkhouser E, Peters E, Schwartz AG, Terry P, Wallace K, Akushevich L, Wang F, Crankshaw S, Moorman PG (2014) A multi-center population-based case - control study of ovarian cancer in African-American women?.: the African American Cancer Epidemiology Study (AACES) BMC Cancer 14: 688.
23. Schildkraut JM, Moorman PG, Halabi S, Calingaert B, Marks JR, Berchuck A (2006) Analgesic drug use and risk of ovarian cancer. Epidemiology 17: 104-107.
24. Schreinemachers D, Everson R (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138-146.
25. Setiawan VW, Matsuno RK, Lurie G, Wilkens LR, Carney ME, Henderson BE, Kolonel LN, Goodman MT (2012) Use of nonsteroidal anti-inflammatory drugs and risk of ovarian and endometrial cancer: the Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev 21: 1441-1449.
26. Trabert B, Ness RB, Lo-Ciganic W-H, Murphy MA, Goode EL, Poole EM, Brinton LA, Webb PM, Nagle CM, Jordan SJ, Risch HA, Rossing MA, Doherty JA, Goodman MT, Lurie G, Kjær SK, Hogdall E, Jensen A, Cramer DW, Terry KL, Vitonis A, Bandera EV, Olson S, King MG, Chandran U, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pearce CL, Pike MC, Berchuck A, Schildkraut JM, Wentzensen N (2014) Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst 106: djt431.
27. Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM (2008) Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br J Cancer 98: 1781-1783.
28. Wu AH, Pearce CL, Tseng C-C, Templeman C, Pike MC (2009) Markers of inflammation and risk of ovarian cancer in Los Angeles county. Int J Cancer 124: 1409-1415.
29. Zhou Y, Boudreau DM, Freedman AN (2014) Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf 23: 43-50.